GlassScriptPhysician profile
Carolyn Davidson
NPI 1043440480
$45,783.78
in general payments reported to CMS, 2019-2025
27 companies · $11K in 2025
The $11K reported for 2025 was more than what 99% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $5,060 · 2022: $3,980 · 2023: $17K · 2024: $9,496 · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $27K · Food and Beverage: $9,101 · Travel and Lodging: $437 · Education: $155.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $27,050.00 |
| Food and Beverage | $9,101.34 |
| Travel and Lodging | $437.02 |
| Education | $154.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $30,515.45 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $6,304.57 | 2022-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Alkermes, INC. | $1,198.78 | 2021-2025 | Aristada, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $1,191.38 | 2021-2025 | Rexulti, Nuedexta, Abilify Maintena |
| Takeda Pharmaceuticals U.S.A., INC. | $946.18 | 2021-2025 | Trintellix |
| Axsome Therapeutics, INC. | $862.37 | 2023-2025 | Auvelity |
| Neurocrine Biosciences, INC. | $718.43 | 2021-2025 | Ingrezza |
| Vanda Pharmaceuticals INC. | $700.27 | 2022-2025 | Fanapt, Hetlioz |
| Corium, LLC | $519.98 | 2022-2025 | Azstarys |
| Lundbeck LLC | $476.84 | 2021-2025 | Rexulti |
| Supernus Pharmaceuticals, INC. | $414.06 | 2021-2025 | Qelbree, Qelbree |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $392.61 | 2021-2024 | Caplyta |
| Almatica Pharma LLC | $385.69 | 2022-2025 | Loreev Xr |
| Janssen Pharmaceuticals, INC | $267.35 | 2021-2025 | Spravato |
| Ironshore Pharmaceuticals INC. | $195.22 | 2022-2024 | Jornay Pm |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adlon Therapeutics L.P. | $122.69 | 2021 | |
| Idorsia Pharmaceuticals US INC | $92.43 | 2022-2024 | Quviviq |
| Collegium Pharmaceutical, INC. | $81.10 | 2025 | Jornay Pm |
| Neos Therapeutics, LP | $80.43 | 2022-2023 | Adzenys Xr-Odt |
| Bausch Health US, LLC | $73.30 | 2021-2022 | |
| Tris Pharma INC | $67.84 | 2024 | Dyanavel Xr |
| Jazz Pharmaceuticals INC. | $37.79 | 2021 | |
| Sage Therapeutics, LLC | $36.79 | 2024-2025 | Zurzuvae |
| Indivior INC. | $34.81 | 2021-2025 | Sublocade |
| Merck Sharp & Dohme LLC | $28.99 | 2021-2022 | |
| Uswm, LLC | $23.87 | 2021 | |
| Biogen, INC. | $14.56 | 2024 | Leqembi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carolyn Davidson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.